First Time Loading...
C

Charmacy Pharmaceutical Co Ltd
HKEX:2289

Watchlist Manager
Charmacy Pharmaceutical Co Ltd
HKEX:2289
Watchlist
Price: 14 HKD Market Closed
Updated: May 21, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

2.8B
-1%
Assets
Growth Rates:
1 Year
+7%
3 Years
+18%
5 Years
+24%
7 Years
+36%
10 Years
-
2.3B
-0.5%
Liabilities
Growth Rates:
1 Year
+7%
3 Years
+19%
5 Years
+25%
7 Years
+39%
10 Years
-
572.8m
-4%
Equity
Growth Rates:
1 Year
+9%
3 Years
+16%
5 Years
+19%
7 Years
+27%
10 Years
-

Balance Sheet Decomposition
Charmacy Pharmaceutical Co Ltd

2.8B
Assets
2.3B
Liabilities
2.8B
Assets
2.3B
Liabilities
Current Assets 2.4B
Cash & Short-Term Investments 445m
Receivables 916.9m
Other Current Assets 1.1B
Non-Current Assets 415.9m
PP&E 308.7m
Intangibles 84.9m
Other Non-Current Assets 22.3m
Current Liabilities 2.2B
Accounts Payable 581.1m
Accrued Liabilities 62.3m
Short-Term Debt 585.1m
Other Current Liabilities 1B
Non-Current Liabilities 14.6m
Long-Term Debt 13.8m
Other Non-Current Liabilities 841k

Balance Sheet
Charmacy Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022
Assets
Cash & Cash Equivalents
17
22
156
477
512
429
506
590
630
493
Cash
17
22
156
3
0
0
1
1
0
1
Cash Equivalents
0
0
0
474
512
428
505
590
630
492
Total Receivables
663
798
977
958
1 010
864
784
821
786
994
Accounts Receivables
658
796
975
861
883
792
712
718
716
844
Other Receivables
5
2
2
98
127
72
72
104
70
150
Inventory
257
245
318
352
432
473
515
585
509
587
Other Current Assets
304
272
397
94
149
197
213
255
313
389
Total Current Assets
1 240
1 337
1 848
1 882
2 103
1 962
2 019
2 251
2 238
2 462
PP&E Net
131
125
118
118
197
218
317
373
348
294
PP&E Gross
131
125
118
118
197
218
317
373
348
294
Accumulated Depreciation
25
34
42
48
56
68
78
93
123
98
Intangible Assets
0
0
0
109
161
159
153
152
143
81
Goodwill
0
0
0
0
5
3
3
6
6
6
Long-Term Investments
0
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
74
72
97
3
6
12
12
17
27
23
Other Assets
0
0
0
0
5
3
3
6
6
6
Total Assets
1 445
N/A
1 534
+6%
2 063
+34%
2 112
+2%
2 472
+17%
2 354
-5%
2 504
+6%
2 799
+12%
2 763
-1%
2 866
+4%
Liabilities
Accounts Payable
873
930
1 292
1 270
1 414
1 343
445
570
533
633
Accrued Liabilities
6
5
12
44
52
43
47
50
49
80
Short-Term Debt
300
301
291
338
523
0
0
536
668
513
Current Portion of Long-Term Debt
0
0
0
0
0
388
531
35
35
4
Other Current Liabilities
56
52
54
17
17
11
855
972
874
1 025
Total Current Liabilities
1 236
1 288
1 649
1 669
2 007
1 786
1 878
2 162
2 159
2 256
Long-Term Debt
0
0
0
0
0
90
141
134
99
16
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
Minority Interest
0
0
0
0
7
0
0
0
0
0
Other Liabilities
0
0
0
0
2
1
1
1
0
0
Total Liabilities
1 236
N/A
1 288
+4%
1 649
+28%
1 669
+1%
2 016
+21%
1 877
-7%
2 020
+8%
2 297
+14%
2 259
-2%
2 271
+1%
Equity
Common Stock
0
0
160
108
108
108
108
108
108
108
Retained Earnings
129
166
146
335
348
369
376
395
396
486
Additional Paid In Capital
80
0
108
0
0
0
0
0
0
0
Total Equity
209
N/A
246
+17%
414
+69%
443
+7%
456
+3%
477
+5%
484
+1%
503
+4%
504
+0%
594
+18%
Total Liabilities & Equity
1 445
N/A
1 534
+6%
2 063
+34%
2 112
+2%
2 472
+17%
2 354
-5%
2 504
+6%
2 799
+12%
2 763
-1%
2 866
+4%
Shares Outstanding
Common Shares Outstanding
80
80
108
108
108
108
108
108
108
108

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.